A pan PAD inhibitor; irreversibly inhibits PAD1-4 (kinact/KI = 16,100, 4,100, 6,800, and 13,300 M-1min-1, respectively); inhibits PMA-induced NET formation in mouse bone marrow-derived neutrophils at 20 and 200 µM; inhibits HSV-1-induced IFN-β production in mouse BMDMs at 1 µM; reduces diABZI STING agonist-1-induced BMDM IFN-β and TNF-α production in wild-type, Pad2-/-, and Pad4-/- mice at 10 mg/kg; increases survival, as well as reduces splenomegaly, myocarditis, and cardiac fibrosis in a Trex1D18N/D18N mouse model of AGS at 20 mg/kg per day